ak 2123 has been researched along with Oropharyngeal Neoplasms in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chatterjee, N; Huilgol, NG; Mehta, AR | 1 |
1 trial(s) available for ak 2123 and Oropharyngeal Neoplasms
| Article | Year |
|---|---|
An overview of the initial experience with AK-2123 as a hypoxic cell sensitizer with radiation in the treatment of advanced head and neck cancers.
Topics: Adult; Aged; Humans; Middle Aged; Neoplasm Staging; Oropharyngeal Neoplasms; Radiation-Sensitizing Agents; Remission Induction; Triazoles | 1996 |